Eviplera
·
- Prescription status not stated
- Antibiotics, antivirals and antifungals taken into the body
- Active substance
- Emtricitabine;rilpivirine;tenofovir disoproxil
- Made by
- Gilead Sciences International Ltd
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
- Eviplera is indicated for the treatment of adults infected with human immunodeficiency virus type 1 (HIV-1) without known mutations associated with resistance to the non-nucleoside reverse transcriptase inhibitor (NNRTI) class, tenofovir or emtricitabine, and with a viral load ? 100,000 HIV-1 RNA copies/mL. As with other antiretroviral medicinal products, genotypic resistance testing and/or historical resistance data should guide the use of Eviplera.
EMA’s data export replaced some characters it could not represent (for example “≥”) with “?”. The text is shown exactly as exported; the wording on the EMA page is authoritative.
From the official label · 2026-09-30 · European Medicines Agency
Same active substance, strength and form in other countries
Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.
Medicine passport: one printable page to show a pharmacist abroad
United StatesNo exact match for this strength and form
SpainNo exact match for this strength and form
CanadaNo exact match for this strength and form
NetherlandsNo exact match for this strength and form
SwitzerlandNo exact match for this strength and form
Details
| Made by | Gilead Sciences International Ltd |
|---|---|
| Active substance | Emtricitabine;rilpivirine;tenofovir disoproxil |
| Used in | Antibiotics, antivirals and antifungals taken into the body |
| Classification | J05AR08 · Antibiotics, antivirals and antifungals taken into the body |
| Authorised on | 2011-11-27 |
| Last updated by the regulator | 2025-12-09 |
| EMA product number | EMEA/H/C/002312 |
Source: European Medicines Agency — medicine data · 2026-09-30 · not reviewed by a clinician
Source: European Medicines Agency (EMA). Product information as published by EMA. Reuse terms: EMA legal notice (reproduction authorised).